Wutah pendapatan kuartal marang kuartal: protalix.com (PLX)

Protalix BioTherapeutics relies on competent management and FDA transparency, which is evidenced by the relative growth in quarterly revenue, where 23.10 shows the current volume of this metric. However, geopolitical tension in Israel is hindering clinical trials and deliveries. Stable income is ensured by the orphan status of the drugs and the partnership with Chiesi, despite strict pricing control by regulators.
Rincian metrik komprehensif lan analitis Protalix BioTherapeutics Inc. (PLX)

This indicator measures operating income dynamics by converting quarterly growth into a daily revenue trajectory. Analyzing the quarterly revenue growth rate allows for an assessment of cash flow stability through the percentage ratio of current and previous periods. The current calculated value of 23.10 reflects the efficiency of product commercialization. For Protalix BioTherapeutics (PLX), this metric is critical, as sales are fully delegated to a global partner.